International Application No PCT/US2004/025592

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/138 A61K31/5375 A61K31/40 A61K31/4025 A61K31/4468 A61K31/538 A61K31/5415 A61K31/40 A61P25/28 A61K31/445 A61K31/439 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, SCISEARCH, WPI Data, PAJ

	Citation of document, with indication, where appropriate, of the	rolo and nacroses	Deleverate state of
ategory *	Citation or document, with indication, where appropriate, or the	relevant passages	Relevant to claim No.
(.	STAHL STEPHEN M: "Neurotransmi cognition, part 2. Selective NR	ls are	1-6
	smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition." THE JOURNAL OF CLINICAL PSYCHIATRY. FEB		
	2003, vol. 64, no. 2, February 2003 (pages 110-111, XP008038406		
	ISSN: 0160-6689 the whole document		
	WO 02/078629 A (DAVIS MICHAEL; KWOK-TUNG (US); RESSLER KERRY J EMORY (U) 10 October 2002 (2002	(US); UNIV	1-6
	abstract page 3, line 15 - line 21 page 6, line 25 - line 30; clai	ms 1 1-6	
		1113 1,4-0	
		-/	
X Furth	ner documents are listed in the continuation of box C.	Patent family members are listed in	n annex.
<u> </u>		Patent family members are listed i T* later document published after the inte	mational filing date
Special cat docume consid	er documents are listed in the continuation of box C. egories of cited documents: Int defining the general state of the art which is not ered to be of particular relevance	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention	rnational filing date the application but sory underlying the
" docume consid " earlier d filling di " docume which i	er documents are listed in the continuation of box C. agories of cited documents: Int defining the general state of the art which is not ered to be of particular relevance ocument but published on or after the international ate Int which may throw doubts on priority claim(s) or scited to establish the publication date of another	"T" later document published after the inte or priority date and not in conflict with clted to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance.	mational filing date the application but sory underlying the laimed invention be considered to cument is taken alone
" docume conside " eartler d filling do " docume which i citation	agories of cited documents: Int defining the general state of the art which is not pered to be of particular relevance ocument but published on or after the International attempt of the publication date of another or or other special reason (as specified) Int referring to an oral disclosure, use, exhibition or	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the c cannot be considered to involve an involve an involve with one or mo ments, such combined with one or mo ments, such combination being obvious	rnational filing date the application but early underlying the laimed invention be considered to cument is taken alone laimed invention rentive step when the re other such docu-
docume docume earlier d filing do docume which i citation docume other n	agories of cited documents: Int defining the general state of the art which is not pered to be of particular relevance ocument but published on or after the International attempt of the publication date of another or or other special reason (as specified) Int referring to an oral disclosure, use, exhibition or	"T" tater document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot linvolve an inventive step when the document of particular relevance; the cannot be considered to involve an inventive step when the document of particular relevance; the cannot be considered to involve an inventive step.	mational filing date the application but sory underlying the laimed invention be considered to current is taken alone laimed invention laimed
docume considered document document which in document document document document document later th	per documents are listed in the continuation of box C. agories of cited documents: Int defining the general state of the art which is not pered to be of particular relevance ocument but published on or after the international attemption of the cited to establish the publication date of another or other special reason (as specified) Int referring to an oral disclosure, use, exhibition or reans Int published prior to the international fliting date but	"T" tater document published after the inte or priority date and not in conflict with cited to understand the principle or the irvention "X" document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the c cannot be considered to involve an inventive step when the document is combined with one or mo ments, such combination being obvious in the art.	rnational filing date the application but sory underlying the laimed invention be considered to cument is taken alone laimed invention ventive step when the re other such docu- st to a person skilled
docume considered filing de docume which i citation docume other in docume later the	er documents are listed in the continuation of box C. agories of cited documents: Int defining the general state of the art which is not ered to be of particular relevance ocument but published on or after the international attemption of the cited to establish the publication date of another or other special reason (as specified) Int referring to an oral disclosure, use, exhibition or the ears Int published prior to the international fliing date but an the priority date claimed	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an indocument is combined with one or moments, such combination being obvious in the art. "8" document member of the same patent	rnational filing date the application but sory underlying the laimed invention be considered to cument is taken alone laimed invention ventive step when the re other such docu- st to a person skilled
pecial cal docume consid. earlier d filing di docume docume other n docume tater th	er documents are listed in the continuation of box C. agories of cited documents: Int defining the general state of the art which is not ered to be of particular relevance ocument but published on or after the international attemption of the cited to establish the publication date of another or other special reason (as specified) Int referring to an oral disclosure, use, exhibition or teans Int published prior to the international fliing date but an the priority date claimed International search	"T" tater document published after the interest or priority date and not in conflict with cited to understand the principle or the invention. "X" document of particular relevance; the considered novel or cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the comment of particular relevance; the comment of particular relevance; the comment is combined with one or moments, such combined with one or moments, such combination being obvious in the art. "8" document member of the same patent.	rnational filing date the application but sory underlying the laimed invention be considered to cument is taken alone laimed invention ventive step when the re other such docu- st to a person skilled

International Application No PCT/US2004/025592

		FC1/0320	04/025592
	alion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
Х	WO 03/049724 A (YANG CHARLES RENKIN; LILLY CO ELI (US); BYMASTER FRANKLIN PORTER (US)) 19 June 2003 (2003-06-19) the whole document		1-6
X	WO 02/053140 A (PHARMACIA AB; SVENSSON TORGNY (SE); WONG ERIK HO FONG (US); UPJOHN CO) 11 July 2002 (2002-07-11) abstract		1-6
	page 2, line 25 - line 31 page 8, line 22 - line 31 page 14, line 30 - page 15, line 10		
A	EP 0 721 777 A (LILLY CO ELI) 17 July 1996 (1996-07-17) the whole document		1-6
A	DE 102 44 537 A (GERLOFF CHRISTIAN; PLEWNIA CHRISTIAN (DE)) 10 April 2003 (2003-04-10) the whole document		1-6
A	WO 02/053104 A (EPSTEIN MEL H; SENTION INC (US); WIIG KJESTEN A (US)) 11 July 2002 (2002-07-11) abstract; claims; examples		1-6
		٠.	
1			
}		·	
			•
-			
}			
	(continuation of second sheet) (January 2004)		<u> </u>

Information on patent family members

International Application No
PCT/US2004/025592

Patent document cited in search report W0 02078629	<u> </u>	Publication date	*.	Patent family member(s)		Publication date
WN 02078629						
MO OLO/OOLS	Α	10-10-2002	CA	2442330		10-10-2002
			EP		A2	28-01-2004
			JP	2004530666	T	07-10-2004
,			WO	02078629		10-10-2002
			US	2004208923	Al	21-10-2004
WO 03049724	Α	19-06-2003	AU	2002352625	A1	23-06-2003
			BR	0213581		24-08-2004
			CA	2467802	A1	19-06-2003
			CZ	20040709	A3	13-10-2004
			EP	1458368		22-09-2004
			HR	20040528	A2	31-10-2004
			SK	2442004	A3	01-12-2004
			WO	03049724		19-06-2003
•			US	2005009925	A1	13-01-2005
WO 02053140	Α	11-07-2002	CA	2431041	A1	11-07-2002
			EP	1353675		22-10-2003
•••			JP	2004517112		10-06-2004
			WO	02053140		11-07-2002
•			US	2002156067	A1	24-10-2002
EP 0721777	Α	17-07-1996	US	5658590	Α	19-08-1997
L. 0/22///		2, 0, 2000	AT		Ť	15-09-2002
			AÜ		B2	12-03-1998
			AÜ	4693896		31-07-1996
•	•		BR	9606903		21-10-1997
			CA	2209735		18-07-1996
			CN	1168095		17-12-1997
			CZ	9702145		14-01-1998
•			DE		D1	02-10-2002
			DE		T2	24-04-2003
			DK		T3	07-10-2002
	•		EP	0721777		17-07-1996
			ES		T3	01-03-2003
•			FI	972922		09-07-1997
	•		HU		A2 ·	28-06-1999
			JP		Ţ	24-11-1998
			NO	973170		02-09-1997
			NZ	301500		28-07-2000
•			PL	321273		24-11-1997
			PT RO	721777 118374	i .	29-11-2002
			RU	2163802	C.S D.T	30-05-2003 10-03-2001
			SI	721777		28-02-2003
•			TR	9700627		21-01-1998
			WO	9621430		18-07-1996
DE 10244537	Α.	10-04-2003	DE	10244537	A1	10-04-2003
WO 02053104	Α	11-07-2002	WO	02053104	 A2	11-07-2002
			7.0	~=~~~~~	, , , ,	31-10-2002

International application No. PCT/US2004/025592

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 1,3-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	ar oxion, via no modificación de ser se ou car
3.	Claims Nos.:
	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	mational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. V	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
'	restricted to the invention first mentioned in the claims; it is covered by claims Nos.;
	1-6 (all partially)
Remark o	on Protest. The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6 (all partially)

Use of atomoxetine or a compound of formula (I) for treating a learning disability

2. claims: 1-5 (all partially)

Use of racemic reboxetine or (S,S) reboxetine for treating a learning disability

3. claims: 1-5 (all partially)

Use of a compound of formula (IA) for treating a learning disability

4. claims: 1-5 (all partially)

Use of a compound of formula (IB),(IC) or (IG) for treating a learning disability

5. claims: 1-5 (all partially)

Use of a compound of formula (ID) for treating a learning disability

6. claims: 1-5 (all partially)

Use of a compound of formula (IE) for treating a learning disability

7. claims: 1-5 (all partially)

Use of a compound of formula (IF) for treating a learning disability ${\bf r}$

8. claims: 1,2,6 (all partially)

Use of atomoxetine or a compound of formula (I) for treating a Motor Skills Disorder

9. claims: 1,2 (all partially)

Use of racemic reboxetine or (S,S) reboxetine for treating a Motor Skills Disorder

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 1,2 (all partially)

Use of a compound of formula (IA) for treating a Motor Skills Disorder

11. claims: 1,2 (all partially)

Use of a compound of formula (IB),(IC),(IG) for treating a Motor Skills Disorder

12. claims: 1,2 (all partially)

Use of a compound of formula (ID) for treating a Motor Skills Disorder

13. claims: 1,2 (all partially)

Use of a compound of formula (IE) for treating a Motor Skills Disorder

14. claims: 1,2 (all partially)

Use of a compound of formula (IF) for treating a Motor Skills Disorder

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Потнер.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.